Article Text

Download PDFPDF

RORgamma agonists enhance survival and memory of type 17 T cells and improve anti-tumor activity
  1. Xiao Hu1,
  2. Jacques Moisan1,
  3. Kinga Majchrzak2,
  4. Chuck Lesch1,
  5. Yahong Wang1,
  6. Brian Sanchez1,
  7. Xikui Liu1,
  8. Rodney Morgan1,
  9. David Mertz1,
  10. Dick Bousley1,
  11. Chad van Huis1,
  12. Don Skalitzky1,
  13. Clarke Taylor1,
  14. Thomas Aicher1,
  15. Peter Toogood1,
  16. Weiping Zou3,
  17. Gary Glick3,
  18. Chrystal Paulos2 and
  19. Laura Carter1
  1. Aff1 grid.476494.cLycera Corp Ann Arbor MI USA
  2. Aff2 grid.259828.c0000000121893475Medical University of South Carolina Charleston SC USA
  3. Aff3 grid.214458.e0000000086837370University of Michigan Ann Arbor MI USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Enhancing tumor-directed immune responses has emerged as an important therapeutic approach to many cancers. Th17/Tc17 cells can mediate robust anti-tumor responses in rodent models and are associated with improved prognosis in some human cancers. RORgt is the key transcription factor controlling the development and function of these cells by supporting the expression of pro-inflammatory cytokines and survival genes while reducing expression of co-inhibitory receptors such as PD-1.


To enhance the function of anti-tumor Type 17 T cells, small molecule RORg agonists were designed. These synthetic agonists, when present during murine and human T cell activation in vitro, increase production of IL-17A and other cytokines/chemokines, and improve cell survival after resting or re-activation.


This improved survival translates to a potent and durable anti-tumor response as adoptive cell therapy using RORg agonist-treated T cells significantly reduces growth of established B16F10 and EG.7 tumors compared to untreated cells. Up to 71 days post transfer, more donor T cells can be recovered from spleens and tumors of mice receiving RORg agonist-treated cells. These cells maintain elevated IL-17 production and reduced co-inhibitory receptor expression suggesting that RORg agonist-induced changes are long-lasting. Interestingly, tumor-specific T cells recovered from mice receiving agonist-treated cells expressed central memory (CD44+CD62L+) or stem-like (CD44-CD62L+) markers vs. the predominantly effector (CD44+CD62L-) cells recovered from animals receiving untreated T cells. In separate experiments, oral administration of RORg agonists significantly inhibits the growth of subcutaneous MC38 and 4T1 tumors in an immune-dependent manner with significantly increased RORg and IL-17 expression in tumors consistent with an increased survival or recruitment of type 17 cells.


By enhancing cytokine production, decreasing co-inhibitory receptor expression while promoting long term survival and self-renewal of T cells, RORg agonists represent a promising immunotherapy approach for the treatment of cancer.